Related by context. Frequent words. (Click for all words.) 73 Altropane 73 oncolytic virus therapies 72 Initiates Phase II 72 Completes Patient Enrollment 71 Receives Orphan Drug Designation 69 ALTROPANE 69 topical non steroidal 68 refractory chronic lymphocytic 68 Presents Positive 68 R sorafenib tablets 68 Panzem R 68 Meets Primary Endpoint 67 Trofex 67 Kuvan R 67 topical anti infective 67 Romidepsin 67 commercializing therapeutic 67 signal detection CTSD 67 topically delivered 66 MKC# 66 ® bortezomib 66 Injectable Suspension 66 inflammatory autoimmune diseases 66 Factor VIIa 66 candidate ridaforolimus 66 VEGFR2 inhibitor 66 BiovaxID TM 66 Onalta 66 Initiate Phase 66 PLK1 SNALP 66 Lipid Polymer Micelle LPM 66 Panzem R NCD 65 candidate brentuximab vedotin 65 immunologic diseases 65 therapeutic monoclonal antibodies 65 2 methoxyestradiol 65 addressing idiopathic pulmonary 65 inflammation autoimmune diseases 65 Advancing Drugs 65 ALN TTR 65 treat male hypogonadism 65 NEBIDO R 65 Nasdaq ENMD 65 ZFP Therapeutics 65 peripherally acting 65 StromaCel Inc. 65 FDA Accepts 65 phenylketonuria PKU developed 65 novel anticancer 65 commercial bioproduction 64 developing Zerenex TM 64 Initiates Phase 64 phenylalanine ammonia lyase 64 cystic fibrosis inflammation autoimmune 64 GVAX R 64 sodium Injection 64 novel RNAi therapeutics 64 treat gastrointestinal disorders 64 fibrosis IPF 64 Hematide TM 64 DNA RNA Medicines 64 metastatic colorectal 64 Develop Novel 64 Kinase Inhibitor 64 liposomal formulation 64 IMC #B 64 GVAX cancer 64 Cotara R 64 Phase Ib clinical trials 64 Small Molecule 64 Fast Track Status 64 Genasense ® oblimersen 64 Inc Therapeutic Competitors 64 Commences Phase 64 interferon gamma 1b 64 Announces FDA Clearance 64 Patient Enrollment 64 EnVivo Pharmaceuticals 64 novel anti infective 64 Enrolls First 64 factor VIIa 64 CEQ# 64 immuno inflammatory diseases 64 Tesetaxel 64 MuGard TM 64 BiTE R 64 Inc. Nasdaq ELGX 64 Idera Pharmaceuticals 64 Inc. Nasdaq INFI 64 RhuDex ® 63 Therapeutic Competitors 63 Completes Enrollment 63 includes investigational compounds 63 Promedior 63 Emergent marketed 63 multi kinase inhibitor 63 Ketotransdel 63 Phase IIb clinical trials 63 Inhalation Solution 63 novel orally administered 63 Daclizumab